Jorge Cortes Selected Research

Myeloid Leukemia (Leukemia, Myelocytic)

4/2015	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
9/2014	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
4/2013	Management of imatinib-resistant patients with chronic myeloid leukemia.
6/2011	Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
2/2011	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
12/2010	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
12/2009	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
7/2008	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
3/2008	Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
3/2007	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jorge Cortes Research Topics

Disease

266	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2022 - 03/2002
135	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 08/2002
77	Neoplasms (Cancer) 01/2021 - 10/2002
70	Leukemia 01/2022 - 03/2002
70	Philadelphia Chromosome 01/2022 - 04/2002
66	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2019 - 07/2002
61	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 03/2002
32	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 03/2003
30	Blast Crisis (Blast Phase) 01/2021 - 05/2002
22	Hematologic Neoplasms (Hematological Malignancy) 05/2020 - 10/2002
19	Acute Promyelocytic Leukemia 01/2019 - 05/2003
18	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2015 - 04/2003
16	Residual Neoplasm 02/2018 - 01/2003
15	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 05/2017 - 06/2003
14	Thrombocytopenia (Thrombopenia) 11/2021 - 06/2004
14	Anemia 01/2021 - 04/2002
14	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 05/2002
13	Myeloid Leukemia (Leukemia, Myelocytic) 04/2015 - 04/2006
10	Polycythemia Vera 04/2017 - 06/2003
10	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 10/2002
9	Diarrhea 01/2021 - 08/2002
9	Pathologic Complete Response 01/2019 - 01/2003
9	Disease Progression 04/2018 - 05/2002
9	Neutropenia 09/2015 - 06/2003
8	Exanthema (Rash) 01/2021 - 06/2009
8	Nausea 09/2018 - 10/2002
7	Fatigue 01/2021 - 01/2003
7	Lymphoma (Lymphomas) 01/2019 - 12/2003
7	Infections 12/2018 - 03/2003
7	Splenomegaly 01/2018 - 06/2010
7	Essential Thrombocythemia 08/2013 - 01/2003
6	Hemorrhage 12/2018 - 06/2009
6	Fibrosis (Cirrhosis) 07/2018 - 07/2004
6	Multiple Myeloma 01/2016 - 03/2003
6	Hypereosinophilic Syndrome (Loeffler Endocarditis) 06/2013 - 09/2002
5	Sepsis (Septicemia) 12/2017 - 11/2004
5	Mucositis 10/2017 - 08/2002
5	Leukocytosis (Pleocytosis) 01/2017 - 12/2003
5	Systemic Mastocytosis 09/2013 - 05/2004
4	Pleural Effusion (Pleural Effusions) 01/2020 - 09/2007

Drug/Important Bio-Agent (IBA)

174	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 05/2002
119	Tyrosine Kinase InhibitorsIBA 11/2022 - 09/2003
42	Dasatinib (BMS 354825)FDA Link 11/2020 - 06/2006
42	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2019 - 03/2002
34	Phosphotransferases (Kinase)IBA 01/2018 - 12/2003
32	nilotinib FDA Link 01/2020 - 07/2005
21	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
20	Decitabine FDA Link 01/2021 - 08/2003
16	bcr-abl Fusion ProteinsIBA 01/2020 - 06/2004
15	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 05/2003
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018 - 03/2002
15	InterferonsIBA 10/2013 - 06/2003
14	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 04/2002
13	ponatinibIBA 01/2022 - 06/2013
13	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 03/2002
13	HomoharringtonineIBA 01/2017 - 04/2002
12	Pharmaceutical PreparationsIBA 01/2021 - 03/2004
12	fludarabineIBA 01/2018 - 03/2003
12	Rituximab (Mabthera)FDA Link 02/2015 - 04/2003
11	fms-Like Tyrosine Kinase 3IBA 01/2021 - 02/2008
11	Monoclonal AntibodiesIBA 01/2021 - 12/2003
11	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 08/2002
10	ruxolitinibIBA 11/2021 - 11/2011
10	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 05/2003
10	Clofarabine (Clolar)FDA Link 07/2015 - 03/2003
9	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 05/2004
9	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2002
9	Dexamethasone (Maxidex)FDA LinkGeneric 05/2015 - 03/2002
8	Prednisone (Sone)FDA LinkGeneric 12/2018 - 10/2009
8	Azacitidine (5 Azacytidine)FDA Link 01/2018 - 10/2007
8	Gemtuzumab (Mylotarg)FDA Link 02/2017 - 12/2002
8	NucleosidesIBA 06/2014 - 12/2003
7	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 03/2012
7	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 02/2008
7	Lenalidomide (CC 5013)FDA Link 01/2016 - 08/2006
7	Alemtuzumab (Campath)FDA Link 06/2013 - 05/2003
7	TransferasesIBA 11/2007 - 03/2003
6	Inotuzumab OzogamicinIBA 01/2021 - 08/2013
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2015 - 03/2002
6	Histone Deacetylase InhibitorsIBA 09/2012 - 08/2006
6	tipifarnib (R115777)IBA 03/2011 - 10/2002
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 07/2002
5	bosutinibIBA 01/2021 - 08/2008
5	BilirubinIBA 12/2018 - 04/2012
5	Reticulin (Reticular Fiber)IBA 01/2018 - 07/2004
5	Valproic Acid (Depakote)FDA LinkGeneric 02/2015 - 05/2005
5	Biological ProductsIBA 09/2013 - 02/2006
5	Oncogene Proteins (Oncogene Protein)IBA 03/2011 - 04/2006
4	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 07/2009
4	blinatumomabIBA 01/2019 - 12/2017
4	Transaminases (Aminotransferases)IBA 12/2018 - 04/2012

Therapy/Procedure

225	Therapeutics 11/2022 - 03/2002
51	Drug Therapy (Chemotherapy) 01/2021 - 03/2002
18	Stem Cell Transplantation 02/2018 - 07/2003
13	Salvage Therapy 11/2020 - 04/2003
13	Induction Chemotherapy 01/2017 - 01/2003
9	Cell Transplantation 12/2020 - 09/2012
8	Drug Tapering 11/2021 - 06/2003
7	Hematopoietic Stem Cell Transplantation 08/2015 - 08/2004
6	Transplantation 05/2017 - 08/2004